Magee M J, Dewey T M, Acuff T, Edgerton J R, Hebeler J F, Prince S L, Mack M J
Cardiopulmonary Research Science and Technology Institute, Dallas, Texas, USA.
Ann Thorac Surg. 2001 Sep;72(3):776-80; discussion 780-1. doi: 10.1016/s0003-4975(01)02840-5.
Myocardial revascularization in diabetic patients is challenging with no established optimum treatment strategy. We reviewed our coronary artery bypass grafting experience to determine the impact of eliminating cardiopulmonary bypass on outcomes in diabetic patients relative to nondiabetic patients.
From January 1995 through December 1999, 9,965 patients, of whom 2,891 (29%) had diabetes, underwent isolated coronary artery bypass grafting. Diabetic and nondiabetic patients were further divided into groups on the basis of cardiopulmonary bypass use. Twelve percent (346 of 2,891) of diabetic patients and 12% (829 of 7,074) of nondiabetic patients underwent coronary artery bypass grafting without cardiopulmonary bypass; the remainder had coronary artery bypass grafting with cardiopulmonary bypass. Nineteen preoperative variables were compared among treatment groups by univariate analysis.
Patients undergoing coronary artery bypass grafting without cardiopulmonary bypass compared with those having coronary artery bypass grafting with cardiopulmonary bypass had higher mean predicted mortalities (diabetic, 3.96% versus 3.72%, p = 0.83; nondiabetic, 3.03% versus 2.86%, p = 0.79). In nondiabetic patients, coronary artery bypass grafting without cardiopulmonary bypass provides an actual and risk-adjusted survival advantage over coronary artery bypass grafting with cardiopulmonary bypass (1.81% versus 3.44%, p = 0.0127; risk-adjusted mortality, 1.79% versus 3.61%, p = 0.007). This survival benefit of coronary artery bypass grafting without cardiopulmonary bypass was not seen in diabetic patients (2.89% versus 3.69%, p = 0.452; risk-adjusted mortality, 2.19% versus 2.98%, p = 0.42). Diabetic patients undergoing coronary artery bypass grafting without cardiopulmonary bypass had fewer complications, including decreased blood product use (34.39% versus 58.4%, p = 0.001), and reduced incidence of prolonged ventilation (6.94% versus 12.10%, p = 0.005), atrial fibrillation (15.90% versus 23.26%, p = 0.002), and renal failure requiring dialysis (0.87% versus 2.75%, p = 0.036).
The survival advantage in nondiabetic patients treated with coronary artery bypass grafting without cardiopulmonary bypass is not apparent in diabetic patients. Coronary artery bypass grafting without cardiopulmonary bypass in diabetic patients is nevertheless associated with a significant reduction in morbidity.
糖尿病患者的心肌血运重建颇具挑战性,尚无既定的最佳治疗策略。我们回顾了我们的冠状动脉旁路移植经验,以确定相对于非糖尿病患者,在糖尿病患者中消除体外循环对治疗结果的影响。
从1995年1月至1999年12月,9965例患者接受了单纯冠状动脉旁路移植术,其中2891例(29%)患有糖尿病。糖尿病患者和非糖尿病患者根据是否使用体外循环进一步分组。12%(2891例中的346例)的糖尿病患者和12%(7074例中的829例)的非糖尿病患者接受了非体外循环冠状动脉旁路移植术;其余患者接受了体外循环冠状动脉旁路移植术。通过单因素分析比较了各治疗组之间的19个术前变量。
与接受体外循环冠状动脉旁路移植术的患者相比,接受非体外循环冠状动脉旁路移植术的患者平均预测死亡率更高(糖尿病患者,3.96%对3.72%,p = 0.83;非糖尿病患者,3.03%对2.86%,p = 0.79)。在非糖尿病患者中,非体外循环冠状动脉旁路移植术比体外循环冠状动脉旁路移植术具有实际的和风险调整后的生存优势(1.81%对3.44%,p = 0.0127;风险调整后死亡率,1.79%对3.61%,p = 0.007)。非体外循环冠状动脉旁路移植术的这种生存益处在糖尿病患者中未观察到(2.89%对3.69%,p = 0.452;风险调整后死亡率,2.19%对2.98%,p = 0.42)。接受非体外循环冠状动脉旁路移植术的糖尿病患者并发症较少,包括血液制品使用减少(34.39%对58.4%,p = 0.001),以及长时间通气发生率降低(6.94%对12.10%,p = 0.005)、心房颤动(15.90%对23.26%,p = 0.002)和需要透析的肾衰竭发生率降低(0.87%对2.75%,p = 0.036)。
非糖尿病患者接受非体外循环冠状动脉旁路移植术的生存优势在糖尿病患者中并不明显。然而,糖尿病患者接受非体外循环冠状动脉旁路移植术与发病率显著降低相关。